These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 2073584

  • 1. In vivo neurochemical and behavioural effects of intracerebrally administered neurotensin and D-Trp11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat.
    Ford AP, Marsden CA.
    Brain Res; 1990 Nov 26; 534(1-2):243-50. PubMed ID: 2073584
    [Abstract] [Full Text] [Related]

  • 2. Neurotensin causes a greater increase in the metabolism of dopamine in the accumbens than in the striatum in vivo.
    Rivest R, Jolicoeur FB, Marsden CA.
    Neuropharmacology; 1991 Jan 26; 30(1):25-33. PubMed ID: 2046877
    [Abstract] [Full Text] [Related]

  • 3. Correlation of increased grooming behavior and motor activity with alterations in nigrostriatal and mesolimbic catecholamines after alpha-melanotropin and neuropeptide glutamine-isoleucine injection in the rat ventral tegmental area.
    Sánchez MS, Barontini M, Armando I, Celis ME.
    Cell Mol Neurobiol; 2001 Oct 26; 21(5):523-33. PubMed ID: 11860189
    [Abstract] [Full Text] [Related]

  • 4. Use of amfonelic acid to discriminate between classical and atypical neuroleptics and neurotensin: an in vivo voltammetric study.
    Rivest R, Jolicoeur FB, Marsden CA.
    Brain Res; 1991 Mar 22; 544(1):86-93. PubMed ID: 1677303
    [Abstract] [Full Text] [Related]

  • 5. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
    Nemeroff CB, Luttinger D, Hernandez DE, Mailman RB, Mason GA, Davis SD, Widerlöv E, Frye GD, Kilts CA, Beaumont K, Breese GR, Prange AJ.
    J Pharmacol Exp Ther; 1983 May 22; 225(2):337-45. PubMed ID: 6682440
    [Abstract] [Full Text] [Related]

  • 6. Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.
    Peltonen I, Myöhänen TT, Männistö PT.
    Neurochem Res; 2012 Sep 22; 37(9):2033-41. PubMed ID: 22729983
    [Abstract] [Full Text] [Related]

  • 7. Muscarinic antagonists attenuate neurotensin-stimulated accumbens and striatal dopamine metabolism.
    Rivest R, Marsden CA.
    Neuroscience; 1992 Sep 22; 47(2):341-9. PubMed ID: 1641127
    [Abstract] [Full Text] [Related]

  • 8. Neurotensin interacts with dopaminergic neurons in rat brain.
    Reches A, Burke RE, Jiang D, Wagner HR, Fahn S.
    Peptides; 1983 Sep 22; 4(1):43-8. PubMed ID: 6866808
    [Abstract] [Full Text] [Related]

  • 9. Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat.
    Kalivas PW, Burgess SK, Nemeroff CB, Prange AJ.
    Neuroscience; 1983 Mar 22; 8(3):495-505. PubMed ID: 6406930
    [Abstract] [Full Text] [Related]

  • 10. Neuropharmacological studies on D145 (1,3-dimethyl-5-aminoadamantan).
    Costall B, Naylor RJ.
    Psychopharmacologia; 1975 Jul 23; 43(1):53-61. PubMed ID: 1099605
    [Abstract] [Full Text] [Related]

  • 11. Modulation of mesolimbic dopaminergic projections by beta-endorphin in the rat.
    Iyengar S, Kim HS, Marien MR, McHugh D, Wood PL.
    Neuropharmacology; 1989 Feb 23; 28(2):123-8. PubMed ID: 2524013
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of amfonelic acid on the haloperidol- and clozapine-induced increase in extracellular DOPAC in the nucleus accumbens and the striatum.
    Rivest R, Marsden CA.
    Synapse; 1992 Jan 23; 10(1):71-8. PubMed ID: 1371367
    [Abstract] [Full Text] [Related]

  • 13. Effects of neurotensin on dopamine release and metabolism in the rat striatum and nucleus accumbens: cross-validation using in vivo voltammetry and microdialysis.
    Blaha CD, Coury A, Fibiger HC, Phillips AG.
    Neuroscience; 1990 Jan 23; 34(3):699-705. PubMed ID: 2352647
    [Abstract] [Full Text] [Related]

  • 14. Serotonin--dopamine interactions in the nigrostriatal system.
    Waldmeier PC, Delini-Stula AA.
    Eur J Pharmacol; 1979 May 15; 55(4):363-73. PubMed ID: 572774
    [Abstract] [Full Text] [Related]

  • 15. Correlation between the discharge rate of non-dopamine neurons in substantia nigra and ventral tegmental area and the motor activity induced by apomorphine.
    Olds ME.
    Neuroscience; 1988 Feb 15; 24(2):465-76. PubMed ID: 3362349
    [Abstract] [Full Text] [Related]

  • 16. Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing.
    Kalivas PW, Nemeroff CB, Prange AJ.
    Neuroscience; 1984 Apr 15; 11(4):919-30. PubMed ID: 6738859
    [Abstract] [Full Text] [Related]

  • 17. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT, White FJ.
    Synapse; 1992 Mar 15; 10(3):206-16. PubMed ID: 1532677
    [Abstract] [Full Text] [Related]

  • 18. Injections of 6-hydroxydopamine in the substantia nigra of the rat brain: morphological and biochemical effects.
    Buonamici M, Cervini MA, Rossi AC, Sebastiani L, Raffaelli A, Bagnoli P.
    Behav Brain Res; 1990 Apr 16; 38(1):83-95. PubMed ID: 2112003
    [Abstract] [Full Text] [Related]

  • 19. Dopamine characteristics in different rat genotypes: the relation to absence epilepsy.
    de Bruin NM, van Luijtelaar EL, Jansen SJ, Cools AR, Ellenbroek BA.
    Neurosci Res; 2000 Oct 16; 38(2):165-73. PubMed ID: 11000443
    [Abstract] [Full Text] [Related]

  • 20. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.
    Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M, Steinberg R, Suaud-Chagny MF, Santucci V, Vita N, Pecceu F, Labbé-Jullié C, Kitabgi P, Soubrié P, Le Fur G, Maffrand JP.
    J Pharmacol Exp Ther; 1997 Feb 16; 280(2):802-12. PubMed ID: 9023294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.